Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo.

Amiodarone is useful for the treatment of ventricular arrhythmias but has been associated with a significant degree of toxicity especially to lung and liver. The drug produces phospholipid accumulation in multilamella lysosomal inclusions in many tissues due to the ability of amiodarone and desethylamiodarone to inhibit phospholipase A. The adverse effects do not correlate with the plasma levels of amiodarone but relate more closely to the cumulative dose. No clear way of predicting amiodarone toxicity has yet emerged. In this report, normal human lymphoblasts in tissue culture were shown by electron microscopy to have dose-dependent increases in multilamellar inclusions when grown with amiodarone at concentrations which are routinely observed in patients receiving the drug. The content of phospholipid also increased but this parameter was not as sensitive as the number of multilamellar inclusions. Finally, lymphocytes from patients treated with amiodarone were examined by electron microscopy and shown to have increased numbers of multilamellar bodies.

[1]  K. Bizière,et al.  Amiodaron neuropathy: further arguments for human drug-induced neurolipidosis. , 1982, European neurology.

[2]  P. Armstrong,et al.  Amiodarone hepatotoxicity simulating alcoholic liver disease. , 1984, The New England journal of medicine.

[3]  M. Josephson,et al.  Amiodarone pulmonary toxicity. , 1982, Annals of internal medicine.

[4]  E. Downar,et al.  Amiodarone pulmonary toxicity: functional and ultrastructural evaluation. , 1986, Thorax.

[5]  E. Downar,et al.  Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. , 1984, Gastroenterology.

[6]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[7]  M. Dake,et al.  Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicity. , 1985, The American journal of medicine.

[8]  N. Mostow,et al.  A general overview of amiodarone toxicity: its prevention, detection, and management. , 1989, Progress in cardiovascular diseases.

[9]  K. Hostetler,et al.  In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. , 1988, Biochimica et biophysica acta.

[10]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[11]  S Kacew,et al.  Amiodarone-induced phospholipidosis in rat alveolar macrophages. , 1988, The American review of respiratory disease.

[12]  K. Hostetler Molecular studies of the induction of cellular phospholipidosis by cationic amphiphilic drugs. , 1984, Federation proceedings.

[13]  M. Reasor,et al.  Amiodarone-induced pulmonary toxicity in rats: biochemical and pharmacological characteristics. , 1989, Toxicology and applied pharmacology.

[14]  K. Hostetler,et al.  Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. , 1986, Biochimica et biophysica acta.

[15]  A. Pesenti,et al.  Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. , 1987, Biochemical pharmacology.

[16]  M. I. Jayson,et al.  The presence of abnormal lysosomes in lymphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study. , 1984, Annals of the rheumatic diseases.